Cannabix Technologies Files FAIMS Cannabis Detection Patent - Enters into License Agreement with University of Florida and Pr...
April 16 2018 - 9:00AM
InvestorsHub NewsWire
501-3292 Production Way,
Burnaby, B.C., V5A 4R4
Phone: (604) 551-7831 Fax: 604-676-2767
info@cannabixtechnologies.com
cannabixtechnologies.com
Cannabix Technologies
Files FAIMS Cannabis Detection Patent
- Enters into License Agreement with University of
Florida and Provides Technology
Update
The Cannabix Marijuana
Breathalyzer is being developed to give law enforcement and
employers a tool to enforce public safety.
Vancouver, British
Columbia -- April
16, 2018 --
InvestorsHub NewsWire -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the "Company or
Cannabix") developer of the Cannabix Marijuana Breathalyzer for law
enforcement and the
workplace, is pleased to report it has
filed a Patent
Cooperation Treaty ("PCT") application titled,
"Device and Method for Detection of Cannabis and Other
Controlled Substances Using FAIMS" (PCT/CA2017/000042).
This PCT covers
intellectual property related to earlier versions of the
Cannabix
Marijuana Breathalyzer. Under its relationship with the
University of Florida ("the
University"), the Company has
entered into
a second license agreement with the
University for PCT application CA2017/000042.
The agreement provides Cannabix exclusive worldwide rights in the
area of breath analysis of controlled substances. Cannabix
is developing an
innovative FAIMS (field asymmetric waveform ion mobility
spectrometry) based instrument for the detection of
9-tetrahydrocannabinol in
human breath.
In recent months the Company has been characterizing its Beta 3.0
Cannabix Marijuana Breathalyzer
prototype performance measures both independently and
coupled to a mass spectrometer (MS), in preparation for expanded
field testing. This work has led to the design and development of
several improvements to the device which are now being
incorporated. The characterizing work has focussed on better
separation of several analytes in human breath that are similar in
molecular mass and geometry to THC. Testing has included further
temperature characterization and flow control. A unique gating
system has been developed that allows switching between the
standalone FAIMS detector and a conventional MS enabling rapid
alternation between both mechanisms during a single breath, proving
enhanced analysis capability.
THC and related metabolite
characterization
Marijuana contains several cannabinoids in
addition to 9-tetrahydrocannabinol (“THC”). Many of these have
shorter half-lives and are metabolized in the body relatively
quickly. THC can be detectable in blood for weeks, whereas
metabolites such as 11-hydroxy-delta-9-tetrahydrocannabinol and
11-nor-9-carboxy-tetrahydrocannabinol are only detectable for a few
hours after consumption of cannabis. The Cannabix FAIMS device has
demonstrated the detection of THC and related metabolites in
MS-coupled testing. The detection of THC and its metabolites in
human breath provides for real-time pharmacokinetic analysis. Such
analysis provides a method for the identification of “recency of
use” and also provides analysis of frequent users of marijuana who
tend to retain THC in their body for longer periods of time,
relative to infrequent marijuana users who tend to clear THC from
their body more quickly. This data and analysis will be important
for an eventual court approved device, furthermore, 11-nor-9-
carboxy-tetrahydrocannabinol is the primary metabolite from the
liver, which is prevalent from the consumption of edibles. Cannabix
scientists are working quickly to complete this characterization
stage.
The Company also reports that it has renewed its
ongoing research agreement for 2018 with the Dr. Yost lab at the
University of Florida.
About Cannabix Technologies
Inc.
Cannabix Technologies Inc. is a leader in
marijuana breathalyzer development for law enforcement and the
workplace. Cannabix has established breath testing technologies in
the pursuit of bringing durable, portable hand-held tools to market
to enhance detection of marijuana impaired driving offences on
roads at a time when marijuana is becoming legal in many global
jurisdictions. Cannabix is working to develop drug-testing devices
that will detect THC- the psychoactive component of marijuana that
causes intoxication- using breath samples. In particular, Cannabix
is focused on developing breath testing devices for detection of
recent use of THC, in contrast to urine testing for THC metabolite
that requires an invasive collection and reflects usage, days or
even weeks earlier. The devices will also be useful for other
practical applications such as testing employees in the workplace
where impairment by THC can be hazardous.
We seek Safe
Harbor.
On behalf of the Board of
Directors
“Rav Mlait”
CEO
Cannabix Technologies Inc.
For further information, contact the Company
at info@cannabixtechnologies.com
The CSE has not reviewed and does not accept
responsibility for the adequacy or accuracy of this
release.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains forward-looking
information that involves various risks and uncertainties regarding
future events. Such forward-looking information can include without
limitation statements based on current expectations involving a
number of risks and uncertainties and are not guarantees of future
performance of the Company, such as final development of a
commercial or prototype product(s), successful trial or pilot of
company technologies, no assurance that commercial sales of any
kind actually materialize; no assurance the Company will have
sufficient funds to complete product development. There are
numerous risks and uncertainties that could cause actual results
and the Company’s plans and objectives to differ materially from
those expressed in the forward-looking information, including: (i)
adverse market conditions; (ii) risks regarding protection of
proprietary technology; (iii) the ability of the Company to
complete financings; (iv) the ability of the Company to develop and
market its future product; and (v) risks regarding government
regulation, managing and maintaining growth, the effect of adverse
publicity, litigation, competition and other factors which may be
identified from time to time in the Company's public announcements
and filings. There is no assurance that the marijuana breathalyzer
business will provide any benefit to the Company, and no assurance
that any proposed new products will be built or proceed. There is
no assurance that existing “patent pending” technologies licensed
by the Company will receive patent status by regulatory
authorities. The Company is not currently selling commercial
breathalyzers. Actual results and future events could differ
materially from those anticipated in such information. These and
all subsequent written and oral forward-looking information are
based on estimates and opinions of management on the dates they are
made and are expressly qualified in their entirety by this notice.
Except as required by law, the Company does not intend to update
these forward-looking statements.
Cannabix Technologies (PK) (USOTC:BLOZF)
Historical Stock Chart
From May 2024 to Jun 2024
Cannabix Technologies (PK) (USOTC:BLOZF)
Historical Stock Chart
From Jun 2023 to Jun 2024